Form 4: Pieris Pharmaceuticals COO Sells Shares
Insider Transaction (Form 4)
Kathleen Goin, Chief Operating Officer of Pieris Pharmaceuticals, Inc., sold 4,302 shares of common stock on August 19, 2026.
Summary
- Option exercise/conversion: acquired 2,154 Common Stock at $7.14 ($15,380) on August 19, 2026; holds 2,154 after (Direct).
- Option exercise/conversion: acquired 2,148 Common Stock at $9.08 ($19,504) on August 19, 2026; holds 4,302 after (Direct).
- Open-market sale: disposed of 1,500 Common Stock at $151.39 ($227,085) on August 19, 2026; holds 2,802 after (Direct).
- Open-market sale: disposed of 1,998 Common Stock at $151.80 ($303,292) on August 19, 2026; holds 804 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $153.00 ($61,199) on August 19, 2026; holds 404 after (Direct).
- Open-market sale: disposed of 102 Common Stock at $155.59 ($15,870) on August 19, 2026; holds 302 after (Direct).
- Open-market sale: disposed of 302 Common Stock at $156.77 ($47,345) on August 19, 2026 (Direct).
- Option exercise/conversion: disposed of 2,154 Stock Option (Right to Buy) on August 19, 2026; holds 4,319 after (Direct).
- Option exercise/conversion: disposed of 2,148 Stock Option (Right to Buy) on August 19, 2026; holds 4,296 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $654,791 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Kathleen Goin — Officer (Chief Operating Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-19 | Option exercise/conversion | Common Stock | 2,154 | $7 | $15.4K | 2,154 |
| 2026-08-19 | Option exercise/conversion | Common Stock | 2,148 | $9 | $19.5K | 4,302 |
| 2026-08-19 | Open-market sale | Common Stock | 1,500 | $151 | $227.1K | 2,802 |
| 2026-08-19 | Open-market sale | Common Stock | 1,998 | $152 | $303.3K | 804 |
| 2026-08-19 | Open-market sale | Common Stock | 400 | $153 | $61.2K | 404 |
| 2026-08-19 | Open-market sale | Common Stock | 102 | $156 | $15.9K | 302 |
| 2026-08-19 | Open-market sale | Common Stock | 302 | $157 | $47.3K | 0 |
| 2026-08-19 | Option exercise/conversion | Stock Option (Right to Buy) | 2,154 | — | — | 4,319 |
| 2026-08-19 | Option exercise/conversion | Stock Option (Right to Buy) | 2,148 | — | — | 4,296 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-19 | Option exercise/conversion (2,154 shares) |
| 2026-08-19 | Option exercise/conversion (2,148 shares) |
| 2026-08-19 | Open-market sale (1,500 shares) |
| 2026-08-19 | Open-market sale (1,998 shares) |
| 2026-08-19 | Open-market sale (400 shares) |
| 2026-08-19 | Open-market sale (102 shares) |
| 2026-08-19 | Open-market sale (302 shares) |
| 2026-08-19 | Option exercise/conversion (2,154 shares) |
| 2026-08-19 | Option exercise/conversion (2,148 shares) |
Keywords
insider transaction, Form 4, PVLA, PALVELLA THERAPEUTICS, INC., bearish, Kathleen Goin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.